Jason Gerberry analyst BAML

Currently out of the existing stock ratings of Jason Gerberry, 143 are a BUY (63.84%), 55 are a HOLD (24.55%), 26 are a SELL (11.61%).

Jason Gerberry

Work Performance Price Targets & Ratings Chart

Analyst Jason Gerberry, employed at BAML, carries an average stock price target met ratio of 61.31% that have a potential upside of 25.95% achieved within 255 days on average.

Jason Gerberry’s has documented 474 price targets and ratings displayed on 47 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 30-May-2024.

Wall Street Analyst Jason Gerberry

Analyst best performing recommendations are on CORI (CORIUM INTERNATIONAL).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $261 was fulfilled within 2 days with a profit of $32.55 (14.25%) receiving and performance score of 71.24.

Average potential price target upside

ABBV AbbVie AGN Allergan plc ALKS Alkermes Plc BHC Bausch Health Companies BLUE Bluebird bio BYSI BeyondSpring ENDP Endo International PLC FGEN FibroGen GLPG Galapagos NV ADR HZNP Horizon Pharma PLC IONS Ionis Pharmaceuticals JAZZ Jazz Pharmaceuticals PLC LLY Eli Lilly and Company MNK Mallinckrodt plc MRK Merck mpany MRTX Mirati Ther MYL Viatris PCVX Vaxcyte  TARS Tarsus Pharmaceuticals  TEVA Teva Pharma Industries Ltd ADR ALLO Allogene Therapeutics BMY Bristol-Myers Squibb Company HRTX Heron Therapeuti MNTA Momenta Pharmaceuticals PFE Pfizer AKRX Akorn ARNA Arena Pharmaceuticals AVDL Avadel Pharmaceuticals PLC CORI Corium International KRTX Karuna Therapeutics PRGO Perrigo Company PLC DICE Dice Molecules Holdings LLC FWP Forward Pharma A S VTRS Viatris OGN Organon ACLX Arcellx AERI Aerie Pharmaceuticals . AMTI Applied Molecular Transport  CARA Cara Therapeutic LYRA Lyra Therapeutics  CHRS Coherus BioSciences RLAY Relay Therapeutics  XENE Xenon Pharmaceuticals AXSM Axsome Therapeutics ARWR Arrowhead Pharmaceuticals HRMY Harmony Biosciences Holdings ITCI Intracellular Th

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

190

$17.87 (10.38%)

180

3 days ago

38/39 (97.44%)

$18.61 (10.86%)

495

Buy

187

$14.87 (8.64%)

195

1 months 23 days ago

10/13 (76.92%)

$27.38 (17.15%)

191

Buy

189

$16.87 (9.80%)

181

4 months 15 days ago

9/11 (81.82%)

$15.71 (9.07%)

252

Buy

195

$22.87 (13.29%)

180

4 months 15 days ago

9/10 (90%)

$21.71 (12.53%)

445

Hold

165

$-7.13 (-4.14%)

157

5 months 4 days ago

11/11 (100%)

$2.96 (1.83%)

314

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Jason Gerberry is most bullish on?

Potential upside of $27.21 has been obtained for ARWR (ARROWHEAD PHARMACEUTICALS)

Which stock is Jason Gerberry is most reserved on?

Potential downside of $3.94 has been obtained for TEVA (TEVA PHARMA INDUSTRIES LTD ADR)

What Year was the first public recommendation made by Jason Gerberry?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?